Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Double-blind, Randomized Clinical Trial With Active Vaccine Control to Evaluate the Safety, Immunogenicity, and Consistency of the Lots of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine in Adults in Brazil

NCT05354024 is registered in ClinicalTrials.gov with Butantan Institute as lead sponsor.

NCT NCT05354024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05354024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Double-blind, Randomized Clinical Trial With Active Vaccine Control to Evaluate the Safety, Immunogenicity, and Consistency of the Lots of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine in Adults in Brazil
Lead sponsor
Butantan Institute
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2023
Completion date
September 25, 2024
Enrollment
4,400 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections, healthy